Summit Therapeutics SMMT 深 沪
等待开盘 08-10 09:30:00 美东时间
13.96
+0.420
+3.10%
华盛通- 最 高14.02
- 今 开13.90
- 成交量 207.57万股
- 最 低 13.105
- 昨 收 13.54
- 总市值 136.98万
- 52周最高 30.05
- 市盈率 静 --
- 换手率 2115.46%
- 52周最低 12.25
- 委 比 88.76%
- 总股本 9.81万
- 历史最高 36.91
- 量 比 0.65
- 振 幅 6.76%
- 历史最低 0.66
- 每 手 1
- 风险率 3.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Summit Therapeutics Plans To Offer $380M Common Shares
https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000119312526314214/d143170d8k.htm
07-24 04:39
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
07-23 19:11
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.
07-23 18:04
HC Wainwright & Co. Downgrades Summit Therapeutics to Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Neutral.
05-22 18:41
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results
Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Esperion, Five9, Atlassian soared while Summit, Crescent, LendingTree fell.
05-02 03:39
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue
US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%. Tech shares jumped 1.6%, energy stocks fell 1.5%.
05-02 02:15
Summit Therapeutics Stock Dips After Q1 Financial Report
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.
05-01 23:12
Earnings Scheduled For February 23, 2026
Companies Reporting Before The Bell • Domino's Pizza (NASDAQ:DPZ) is likely to ...
02-23 19:11
Preview: Summit Therapeutics's Earnings
Summit Therapeutics (NASDAQ:SMMT) will release its quarterly earnings report on...
02-20 22:02
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway
The FDA accepted Summit Therapeutics' application for its lung cancer drug ivonescimab, setting a November 2026 decision date after positive Phase 3 trial results.
01-30 01:28
